{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:31:45Z","timestamp":1779100305108,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0210072"],"award-info":[{"award-number":["JP21fk0210072"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0310101"],"award-info":[{"award-number":["JP21fk0310101"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0210047"],"award-info":[{"award-number":["JP21fk0210047"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0210064"],"award-info":[{"award-number":["JP21fk0210064"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0210056"],"award-info":[{"award-number":["JP21fk0210056"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0210048"],"award-info":[{"award-number":["JP21fk0210048"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0210058"],"award-info":[{"award-number":["JP21fk0210058"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0210066"],"award-info":[{"award-number":["JP21fk0210066"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0210067"],"award-info":[{"award-number":["JP21fk0210067"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K08458"],"award-info":[{"award-number":["19K08458"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to evaluate factors associated with changes in skeletal muscle mass in hepatitis C virus (HCV)-infected patients after treatment with direct-acting antivirals (DAAs). Consecutive HCV-infected patients after treatment with DAA were recruited into the study. Patients who achieved sustained virological response (SVR); and had complete clinical information, preserved serum samples at baseline and SVR48, and skeletal muscle mass evaluations based on the psoas muscle mass index (PMI) on computed tomography at baseline and\u2009\u2265\u200912\u00a0months were included. Altogether, 70.7% of patients (41\/58) showed increased PMI after DAA therapy, and mean relative PMI was significantly higher after DAA therapy than at baseline. There were no significant associations between baseline clinical factors routinely examined in clinical practice and increased PMI. Among factors reported to be associated with skeletal muscle loss in patients with chronic liver disease, serum zinc levels and total and free carnitine levels increased significantly after DAA therapy and only changes in serum free carnitine levels were significantly associated with an increased PMI (<jats:italic>r<\/jats:italic>\u2009=\u20090305, <jats:italic>P<\/jats:italic>\u2009=\u20090.020). In conclusion, increased skeletal muscle mass after successful HCV eradication by DAAs was significantly associated with increased serum-free carnitine levels. <jats:sc>l<\/jats:sc>-carnitine supplementation may be beneficial in patients with low skeletal muscle mass after DAA.<\/jats:p>","DOI":"10.1038\/s41598-021-96203-z","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T10:03:52Z","timestamp":1629108232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals"],"prefix":"10.1038","volume":"11","author":[{"given":"Yoshimasa","family":"Tokuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kitagataya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonoe","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuharu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kawagishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Sho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuteru","family":"Natsuizaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"issue":"Suppl 1","key":"96203_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/ajt.12021","volume":"13","author":"WR Kim","year":"2013","unstructured":"Kim, W. R. et al. OPTN\/SRTR 2011 annual data report: Liver. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg. 13(Suppl 1), 73\u2013102. https:\/\/doi.org\/10.1111\/ajt.12021 (2013).","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg."},{"key":"96203_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00535-017-1353-y","volume":"53","author":"G Suda","year":"2018","unstructured":"Suda, G. et al. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: A nationwide retrospective study in Japan. J. Gastroenterol. 53, 119\u2013128. https:\/\/doi.org\/10.1007\/s00535-017-1353-y (2018).","journal-title":"J. Gastroenterol."},{"key":"96203_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","volume":"54","author":"T Takehara","year":"2019","unstructured":"Takehara, T. et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: An open-label phase 3 trial. J. Gastroenterol. 54, 87\u201395. https:\/\/doi.org\/10.1007\/s00535-018-1503-x (2019).","journal-title":"J. Gastroenterol."},{"key":"96203_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00535-017-1427-x","volume":"53","author":"G Suda","year":"2018","unstructured":"Suda, G., Ogawa, K., Morikawa, K. & Sakamoto, N. Treatment of hepatitis C in special populations. J. Gastroenterol. 53, 591\u2013605. https:\/\/doi.org\/10.1007\/s00535-017-1427-x (2018).","journal-title":"J. Gastroenterol."},{"key":"96203_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15189","author":"G Suda","year":"2020","unstructured":"Suda, G. & Sakamoto, N. Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems. J. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1111\/jgh.15189 (2020).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"96203_CR6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","volume":"67","author":"H Nagata","year":"2017","unstructured":"Nagata, H. et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J. Hepatol. 67, 933\u2013939. https:\/\/doi.org\/10.1016\/j.jhep.2017.05.028 (2017).","journal-title":"J. Hepatol."},{"key":"96203_CR7","doi-asserted-by":"publisher","first-page":"9207","DOI":"10.1038\/s41598-021-88632-7","volume":"11","author":"N Kawagishi","year":"2021","unstructured":"Kawagishi, N. et al. Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. Sci. Rep. 11, 9207. https:\/\/doi.org\/10.1038\/s41598-021-88632-7 (2021).","journal-title":"Sci. Rep."},{"key":"96203_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/hepr.13490","volume":"50","author":"N Kawagishi","year":"2020","unstructured":"Kawagishi, N. et al. High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. Hepatol. Res. 50, 671\u2013681. https:\/\/doi.org\/10.1111\/hepr.13490 (2020).","journal-title":"Hepatol. Res."},{"key":"96203_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209615","volume":"13","author":"N Kawagishi","year":"2018","unstructured":"Kawagishi, N. et al. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS ONE 13, e0209615. https:\/\/doi.org\/10.1371\/journal.pone.0209615 (2018).","journal-title":"PLoS ONE"},{"key":"96203_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/hepr.12999","volume":"48","author":"R Sugimoto","year":"2018","unstructured":"Sugimoto, R. et al. Changes in liver function and body composition by direct-acting antiviral therapy for hepatitis C virus infection. Hepatol. Res. 48, 337\u2013344. https:\/\/doi.org\/10.1111\/hepr.12999 (2018).","journal-title":"Hepatol. Res."},{"key":"96203_CR11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/jvh.13484","volume":"28","author":"Y Tokuchi","year":"2021","unstructured":"Tokuchi, Y. et al. Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass. J. Viral Hepat. 28, 755\u2013763. https:\/\/doi.org\/10.1111\/jvh.13484 (2021).","journal-title":"J. Viral Hepat."},{"key":"96203_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ageing\/afq034","volume":"39","author":"AJ Cruz-Jentoft","year":"2010","unstructured":"Cruz-Jentoft, A. J. et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39, 412\u2013423. https:\/\/doi.org\/10.1093\/ageing\/afq034 (2010).","journal-title":"Age Ageing"},{"key":"96203_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s13539-012-0069-3","volume":"3","author":"S Dasarathy","year":"2012","unstructured":"Dasarathy, S. Consilience in sarcopenia of cirrhosis. J. Cachexia Sarcopenia Muscle 3, 225\u2013237. https:\/\/doi.org\/10.1007\/s13539-012-0069-3 (2012).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"96203_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/hepr.12616","volume":"46","author":"T Hanai","year":"2016","unstructured":"Hanai, T. et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatol. Res. 46, 743\u2013751. https:\/\/doi.org\/10.1111\/hepr.12616 (2016).","journal-title":"Hepatol. Res."},{"key":"96203_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00535-014-0964-9","volume":"50","author":"S Iritani","year":"2015","unstructured":"Iritani, S. et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J. Gastroenterol. 50, 323\u2013332. https:\/\/doi.org\/10.1007\/s00535-014-0964-9 (2015).","journal-title":"J. Gastroenterol."},{"key":"96203_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/lt.23811","volume":"20","author":"T Masuda","year":"2014","unstructured":"Masuda, T. et al. Sarcopenia is a prognostic factor in living donor liver transplantation. Liver Transpl. 20, 401\u2013407. https:\/\/doi.org\/10.1002\/lt.23811 (2014).","journal-title":"Liver Transpl."},{"key":"96203_CR17","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/hepr.12774","volume":"46","author":"H Nishikawa","year":"2016","unstructured":"Nishikawa, H. et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol. Res. 46, 951\u2013963. https:\/\/doi.org\/10.1111\/hepr.12774 (2016).","journal-title":"Hepatol. Res."},{"key":"96203_CR18","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/hep4.1207","volume":"2","author":"M Ohara","year":"2018","unstructured":"Ohara, M. et al. L-carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis. Hepatol. Commun. 2, 906\u2013918. https:\/\/doi.org\/10.1002\/hep4.1207 (2018).","journal-title":"Hepatol. Commun."},{"key":"96203_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/jcm8030336","volume":"8","author":"H Nishikawa","year":"2019","unstructured":"Nishikawa, H. et al. Serum zinc concentration and sarcopenia: A close linkage in chronic liver diseases. J. Clin. Med. 8, 2. https:\/\/doi.org\/10.3390\/jcm8030336 (2019).","journal-title":"J. Clin. Med."},{"key":"96203_CR20","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2169\/internalmedicine.6029-20","volume":"60","author":"R Sakamori","year":"2021","unstructured":"Sakamori, R. et al. Improvement of skeletal muscle mass after ledipasvir and sofosbuvir treatment for hepatitis C virus in decompensated liver cirrhosis. Intern. Med. 60, 745\u2013750. https:\/\/doi.org\/10.2169\/internalmedicine.6029-20 (2021).","journal-title":"Intern. Med."},{"key":"96203_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10735-010-9270-x","volume":"41","author":"L Ceglia","year":"2010","unstructured":"Ceglia, L. et al. Multi-step immunofluorescent analysis of vitamin D receptor loci and myosin heavy chain isoforms in human skeletal muscle. J. Mol. Histol. 41, 137\u2013142. https:\/\/doi.org\/10.1007\/s10735-010-9270-x (2010).","journal-title":"J. Mol. Histol."},{"key":"96203_CR22","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/jcb.23444","volume":"113","author":"CG Buitrago","year":"2012","unstructured":"Buitrago, C. G., Arango, N. S. & Boland, R. L. 1alpha,25(OH)2D3-dependent modulation of Akt in proliferating and differentiating C2C12 skeletal muscle cells. J. Cell Biochem. 113, 1170\u20131181. https:\/\/doi.org\/10.1002\/jcb.23444 (2012).","journal-title":"J. Cell Biochem."},{"key":"96203_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0168-8278(97)80315-7","volume":"27","author":"N Assy","year":"1997","unstructured":"Assy, N. et al. Growth hormone-stimulated insulin-like growth factor (IGF) I and IGF-binding protein-3 in liver cirrhosis. J. Hepatol. 27, 796\u2013802 (1997).","journal-title":"J. Hepatol."},{"key":"96203_CR24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S0168-8278(02)00049-1","volume":"36","author":"AJ Donaghy","year":"2002","unstructured":"Donaghy, A. J., Delhanty, P. J., Ho, K. K., Williams, R. & Baxter, R. C. Regulation of the growth hormone receptor\/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. J. Hepatol. 36, 751\u2013758 (2002).","journal-title":"J. Hepatol."},{"key":"96203_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.bbrc.2003.07.016","volume":"313","author":"H Moriwaki","year":"2004","unstructured":"Moriwaki, H. et al. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem. Biophys. Res. Commun. 313, 405\u2013409 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"96203_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1743-7075-7-30","volume":"7","author":"JL Flanagan","year":"2010","unstructured":"Flanagan, J. L., Simmons, P. A., Vehige, J., Willcox, M. D. & Garrett, Q. Role of carnitine in disease. Nutr. Metab. 7, 30. https:\/\/doi.org\/10.1186\/1743-7075-7-30 (2010).","journal-title":"Nutr. Metab."},{"key":"96203_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/BF03261931","volume":"51","author":"SE Reuter","year":"2012","unstructured":"Reuter, S. E. & Evans, A. M. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin. Pharmacokinet 51, 553\u2013572 (2012).","journal-title":"Clin. Pharmacokinet"},{"key":"96203_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25010182","author":"A Gnoni","year":"2020","unstructured":"Gnoni, A., Longo, S., Gnoni, G. V. & Giudetti, A. M. Carnitine in human muscle bioenergetics: can carnitine supplementation improve physical exercise?. Molecules https:\/\/doi.org\/10.3390\/molecules25010182 (2020).","journal-title":"Molecules"},{"key":"96203_CR29","first-page":"17","volume":"16","author":"AH Mitwalli","year":"2005","unstructured":"Mitwalli, A. H. et al. L-carnitine supplementation in hemodialysis patients. Saudi J. Kidney Dis. Transpl. 16, 17\u201322 (2005).","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"96203_CR30","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1172\/JCI108824","volume":"60","author":"CWS Daniel Rudman","year":"1977","unstructured":"Daniel Rudman, C. W. S. & Joseph, D. A. Deficiency of carnitine in cachectic cirrhotic patients. J. Clin. Investig. 60, 716\u2013723 (1977).","journal-title":"J. Clin. Investig."},{"key":"96203_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1258\/002367788780746511","volume":"22","author":"T Koizumi","year":"1988","unstructured":"Koizumi, T., Nikaido, H., Hayakawa, J., Nonomura, A. & Yoneda, T. Infantile disease with microvesicular fatty infiltration of viscera spontaneously occurring in the C3H-H-2(0) strain of mouse with similarities to Reye\u2019s syndrome. Lab. Anim. 22, 83\u201387 (1988).","journal-title":"Lab. Anim."},{"key":"96203_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1750-1172-7-68","volume":"7","author":"PL Magoulas","year":"2012","unstructured":"Magoulas, P. L. & El-Hattab, A. W. Systemic primary carnitine deficiency: An overview of clinical manifestations, diagnosis, and management. Orphanet. J. Rare Dis. 7, 68. https:\/\/doi.org\/10.1186\/1750-1172-7-68 (2012).","journal-title":"Orphanet. J. Rare Dis."},{"key":"96203_CR33","doi-asserted-by":"publisher","first-page":"618S","DOI":"10.1093\/ajcn\/72.2.618S","volume":"72","author":"EP Brass","year":"2000","unstructured":"Brass, E. P. Supplemental carnitine and exercise. Am. J. Clin. Nutr. 72, 618S-623S (2000).","journal-title":"Am. J. Clin. Nutr."},{"key":"96203_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083a0","volume":"387","author":"AC McPherron","year":"1997","unstructured":"McPherron, A. C., Lawler, A. M. & Lee, S. J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387, 83\u201390. https:\/\/doi.org\/10.1038\/387083a0 (1997).","journal-title":"Nature"},{"key":"96203_CR35","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/jmv.24692","volume":"89","author":"Y Tsukuda","year":"2017","unstructured":"Tsukuda, Y. et al. Anti-adipogenic and antiviral effects of l-carnitine on hepatitis C virus infection. J. Med. Virol. 89, 857\u2013866. https:\/\/doi.org\/10.1002\/jmv.24692 (2017).","journal-title":"J. Med. Virol."},{"key":"96203_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s13539-011-0017-7","volume":"2","author":"R Silverio","year":"2011","unstructured":"Silverio, R., Laviano, A., Rossi Fanelli, F. & Seelaender, M. l-carnitine and cancer cachexia: Clinical and experimental aspects. J. Cachexia Sarcopenia Muscle 2, 37\u201344. https:\/\/doi.org\/10.1007\/s13539-011-0017-7 (2011).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"96203_CR37","doi-asserted-by":"publisher","first-page":"13566","DOI":"10.1038\/s41598-020-70585-y","volume":"10","author":"H Nakanishi","year":"2020","unstructured":"Nakanishi, H. et al. Impaired brain function improved by L-carnitine in patients with cirrhosis: Evaluation using near-infrared spectroscopy. Sci. Rep. 10, 13566. https:\/\/doi.org\/10.1038\/s41598-020-70585-y (2020).","journal-title":"Sci. Rep."},{"key":"96203_CR38","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cgh.2014.12.005","volume":"13","author":"H Nakanishi","year":"2015","unstructured":"Nakanishi, H. et al. L-carnitine reduces muscle cramps in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 13, 1540\u20131543. https:\/\/doi.org\/10.1016\/j.cgh.2014.12.005 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"96203_CR39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/hepr.13499","volume":"50","author":"M Ohara","year":"2020","unstructured":"Ohara, M. et al. Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. Hepatol. Res. 50, 715\u2013725. https:\/\/doi.org\/10.1111\/hepr.13499 (2020).","journal-title":"Hepatol. Res."},{"key":"96203_CR40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/rco2.20","volume":"3","author":"M Ohara","year":"2020","unstructured":"Ohara, M. et al. Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. JCSM Rapid Commun. 3, 103\u2013114. https:\/\/doi.org\/10.1002\/rco2.20 (2020).","journal-title":"JCSM Rapid Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96203-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96203-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96203-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:45:45Z","timestamp":1670071545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96203-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["96203"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-96203-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"8 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Professor Naoya Sakamoto received lecture fees from Bristol Myers Squibb and Pharmaceutical K. K., grants and endowments from MSD K. K and Chugai Pharmaceutical Co., Ltd., and a research grant from Gilead Sciences Inc. Dr. Goki Suda received research grants from Bristol Myers Squibb. The other authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16616"}}